CORE--PHARMACOLOGY

$250,404P30FY2002CANIH

University Of Colorado Denver, Aurora CO

Investigators

Linked publications, trials & patents

Paper 39763739 Paper 39737640 Paper 39726772 Paper 39711559 Paper 39711135 Paper 39684443 Paper 39677775 Paper 39677720 Paper 39677022 Paper 39671500 Paper 39671496 Paper 39630148 Paper 39609428 Paper 39604567 Paper 39603869 Paper 39574899 Paper 39564580 Paper 39554114 Paper 39436696 Paper 39400608 Paper 39384405 Paper 39342284 Paper 39321266 Paper 39311710 Paper 39282307 Paper 39266537 Paper 39264810 Paper 39215796 Paper 39201277 Paper 39191549 Paper 39147413 Paper 39139560 Paper 39136655 Paper 39120971 Paper 39091762 Trial NCT05073848 Trial NCT05053737 Trial NCT05006040 Trial NCT04993859 Trial NCT04988490 Trial NCT04973007 Trial NCT04963283 Trial NCT04940468 Trial NCT04925193 Trial NCT04922112 Trial NCT04916990 Trial NCT04882111 Trial NCT04866758 Trial NCT04863092 Trial NCT04634110 Trial NCT04611022 Trial NCT04565457 Trial NCT04558138 Trial NCT04544592 Trial NCT04541407 Trial NCT04535102 Trial NCT04520867 Trial NCT04486573 Trial NCT04471363 Trial NCT04408092 Trial NCT04305366 Trial NCT04300478 Trial NCT04294693 Trial NCT04208243 Trial NCT04092803 Trial NCT04091867 Trial NCT04066218 Trial NCT04042935 Trial NCT04035408 Trial NCT04028167 Trial NCT04028063 Trial NCT04001101 Trial NCT03995082 Trial NCT03976193 Trial NCT03970226 Trial NCT03958565 Trial NCT03900793 Trial NCT03891654 Trial NCT03881098 Trial NCT03781154 Trial NCT03734653 Trial NCT03617679 Trial NCT03325634 Trial NCT01886859 Trial NCT01426334 Trial NCT01232829 Trial NCT00778167 Patent 9434994 Patent 8734778 Patent 8715649 Patent 8343502 Patent 8337830 Patent 8221763 Patent 8153136 Patent 8067559 Patent 7910315 Patent 7595060 Patent 7563447 Patent 7465454 Patent 7083787

Abstract

Description: (Applicant's Description) The Pharmacology Core provides support to investigators for the analytical and mathematical analysis of pharmacokinetic data generated in both basic research and clinical settings. The services offered by the Core cover 3 areas: (1) advice on the design and implementation of pharmacokinetic studies; (2) development and implementation of sensitive, precise and accurate quantitative assays for drugs and drug metabolites in biological tissues and fluids; and (3) pharmacokinetic modeling of analytical data. The facility is be co-directed by Drs. Mark Duncan and Daniel Gustafson, both new UCCC members. They have been given adjacent laboratories and office space to facilitate optimal interaction. Quantitative analytical techniques are based on a range of options including HPLC with UV/Vis, fluorometric and MS detectors, GC/MS, as well as other appropriate techniques (i.e. RIA, ELISA, enzymatic). Pharmacokinetic modeling services include compartmental, non-compartmental and physiologically-based analyses using state-of-the-art software. The Core was established as a developing core and resources for its development came from CCSG development sources, Cancer Center funds, an NIH shared equipment grant and from the Schools of Pharmacy and Medicine. The institution of this Core coincides with the expansion of the Developmental Therapeutics program and its phase 1 trial component. In addition, however, other program members use the Core for pre-clinical and early phase II trials, including members from Hormone Related Malignancies, Tobacco Related Malignancies, Radiation Oncology and Carcinogenesis & Chemoprevention. The Pharmacology Core is a major new Cancer Center initiative that will require the hiring of additional personnel as Core usage increases. However, all the necessary equipment is available and fully operational. The facility will move to Fitzsimons in 2002 when the research complex I is completed at that site.

View original record on NIH RePORTER →